Rodrigo M. Corder

Rodrigo M. Corder

Auto-generated profile, based on publicly available information

Rodrigo M. Corder

Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo , São Paulo

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2020 in medRxiv
Verified
Preprint
Open access
PDF file
MGM. Gabriela M. Gomes
M. Gabriela M. Gomes
MFMarcelo U. Ferreira
Marcelo U. Ferreira
RCRodrigo M. Corder
Rodrigo M. Corder
JKJessica G. King
Jessica G. King
CSCaetano Souto-Maior
Caetano Souto-Maior
RARicardo Aguas
Ricardo Aguas
Individual variation in susceptibility and exposure is subject to selection by natural infection, accelerating the acquisition of immunity, and reducing herd immunity thresholds and epidemic final sizes. This is a manifestation of a wider population phenomenon known as “frailty variation”. Despite theoretical understanding, public health policies continue to be guided by mathematical models that leave out considerable variation and as a result inflate projected disease burdens and overestimate the impact of interventions. Here we focus on trajectories of the coronavirus disease (COVID-19) pandemic in England and Scotland until November 2021. We fit models to series of daily deaths and infer relevant epidemiological parameters, including coefficients of variation and effects of non-pharmaceutical interventions which we find in agreement with independent empirical estimates based on contact surveys. Our estimates are robust to whether the analysed data series encompass one or two pandemic waves and enable projections compatible with subsequent dynamics. We conclude that vaccination programmes may have contributed modestly to the acquisition of herd immunity in populations with high levels of pre-existing naturally acquired immunity, while being critical to protect vulnerable individuals from severe outcomes as the virus becomes endemic. Graphical Highlights: Variation in susceptibility/exposure responds to selection by natural infection Selection on susceptibility/exposure flattens epidemic curves Models with incomplete heterogeneity overestimate intervention impacts Individual variation lowered the natural herd immunity threshold for SARS-CoV-2

10 July 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
RCRebeca Carballar-Lejarazú
Rebeca Carballar-Lejarazú
YDYuemei Dong
Yuemei Dong
TPThai Binh Pham
Thai Binh Pham
TTTaylor Tushar
Taylor Tushar
RCRodrigo M. Corder
Rodrigo M. Corder
AJAnthony James
Anthony James
Proposed genetic approaches for reducing human malaria include population modification, which introduces genes into vector mosquitoes to reduce or prevent parasite transmission. We demonstrate the potential of Cas9/guide RNA (gRNA)–based gene-drive systems linked to dual antiparasite effector genes to spread rapidly through mosquito populations. Two strains have an autonomous gene-drive system coupled to dual anti- Plasmodium falciparum effector genes comprising single-chain variable fragment monoclonal antibodies targeting parasite ookinetes and sporozoites in the African malaria mosquitoes Anopheles gambiae (AgTP13) and Anopheles coluzzii (AcTP13). The gene-drive systems achieved full introduction within 3 to 6 mo after release in small cage trials. Life-table analyses revealed no fitness loads affecting AcTP13 gene-drive dynamics but AgTP13 males were less competitive than wild types. The effector molecules reduced significantly both parasite prevalence and infection intensities. These data supported transmission modeling of conceptual field releases in an island setting that shows meaningful epidemiological impacts at different sporozoite threshold levels (2.5 to 10 k) for human infection by reducing malaria incidence in optimal simulations by 50 to 90% within as few as 1 to 2 mo after a series of releases, and by ≥90% within 3 mo. Modeling outcomes for low sporozoite thresholds are sensitive to gene-drive system fitness loads, gametocytemia infection intensities during parasite challenges, and the formation of potentially drive-resistant genome target sites, extending the predicted times to achieve reduced incidence. TP13-based strains could be effective for malaria control strategies following validation of sporozoite transmission threshold numbers and testing field-derived parasite strains. These or similar strains are viable candidates for future field trials in a malaria-endemic region.

1 April 2021 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
MFMarcelo U. Ferreira
Marcelo U. Ferreira
TSTais Nobrega de Sousa
Tais Nobrega de Sousa
GRGabriel W. Rangel
Gabriel W. Rangel
Igor Cavallini JohansenIgor Cavallini Johansen
Igor Cavallini Johansen
RCRodrigo M. Corder
Rodrigo M. Corder
JGJosé Pedro Gil
José Pedro Gil
Emerging antimalarial drug resistance may undermine current efforts to control and eliminate Plasmodium vivax, the most geographically widespread yet neglected human malaria parasite. Endemic countries are expected to assess regularly the therapeutic efficacy of antimalarial drugs in use in order to adjust their malaria treatment policies, but proper funding and trained human resources are often lacking to execute relatively complex and expensive clinical studies, ideally complemented by ex vivo assays of drug resistance. Here we review the challenges for assessing in vivo P. vivax responses to commonly used antimalarials, especially chloroquine and primaquine, in the presence of confounding factors such as variable drug absorption, metabolism and interaction, and the risk of new infections following successful radical cure. We introduce a simple modeling approach to quantify the relative contribution of relapses and new infections to recurring parasitemias in clinical studies of hypnozoitocides. Finally, we examine recent methodological advances that may render ex vivo assays more practical and widely used to confirm P. vivax drug resistance phenotypes in endemic settings and review current approaches to the development of robust genetic markers for monitoring chloroquine resistance in P. vivax populations.

24 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
RARicardo Aguas
Ricardo Aguas
GGGuilherme Gonçalves
Guilherme Gonçalves
MFMarcelo U. Ferreira
Marcelo U. Ferreira
MGM. Gabriela M. Gomes
M. Gabriela M. Gomes
RCRodrigo M. Corder
Rodrigo M. Corder
JKJessica G. King
Jessica G. King
Variation in individual susceptibility or frequency of exposure to infection accelerates the rate at which populations acquire immunity by natural infection. Individuals that are more susceptible or more frequently exposed tend to be infected earlier and hence more quickly selected out of the susceptible pool, decelerating the incidence of new infections as the epidemic progresses. Eventually, susceptible numbers become low enough to prevent epidemic growth or, in other words, the herd immunity threshold (HIT) is reached. We have recently proposed a method whereby mathematical models, with gamma distributions of susceptibility or exposure to SARS-CoV-2, are fitted to epidemic curves to estimate coefficients of individual variation among epidemiological parameters of interest. In the initial study we estimated HIT around 25-29% for the original Wuhan virus in England and Scotland. Here we explore the limits of applicability of the method using Spain and Portugal as case studies. Results are robust and consistent with England and Scotland, in the case of Spain, but fail in Portugal due to particularities of the dataset. We describe failures, identify their causes, and propose methodological extensions.

5 July 2018 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
APAnaclara Pincelli
Anaclara Pincelli
PNPaulo Augusto Neves
Paulo Augusto Neves
BLBárbara Hatzlhoffer Lourenço
Bárbara Hatzlhoffer Lourenço
RCRodrigo M. Corder
Rodrigo M. Corder
MMMaíra B. Malta
Maíra B. Malta
FGfor the MINA Brazil Working Group
for the MINA Brazil Working Group
We measured the prevalence of malaria in pregnancy and estimated its impact on birth weight and length and maternal hemoglobin in 1,180 women from Juruá Valley, the main malaria hotspot in Brazil. Antenatal malaria episodes, 74.6% of them due to Plasmodium vivax, were microscopically diagnosed in 8.0% of the women and were associated with an average reduction in birth weight z-scores of 0.35 (95% confidence interval [CI] = 0.14–0.57) and in birth length z-scores of 0.31 (95% CI = 0.08–0.54), compared with malaria-free pregnancies. Affected mothers had a mean decrease in hemoglobin concentration at delivery of 0.33 g/100 mL (95% CI = 0.05–0.62 g/100 mL); 51.6% were anemic. The timing and frequency of antenatal infections influenced pregnancy outcomes and first- or second-trimester infections were not associated with decreased birth weight and length and maternal hemoglobin at delivery. Although repeated antenatal vivax infections were associated with poorer birth outcomes, even a single vivax malaria episode was associated with a significant reduction in birth weight and length and maternal hemoglobin. Overall, 7.5% women had the parasite’s DNA found in peripheral blood at delivery. Most (83.1%) of these 89 perinatal infections were due to P. vivax and only 7.9% of them progressed to symptomatic disease after delivery. Plasmodium vivax and Plasmodium falciparum DNA was found in 0.6% and 0.3% of 637 cord blood samples examined, respectively, but only one newborn developed clinical neonatal malaria. Our results further challenge the notion that vivax malaria is relatively benign during pregnancy and call for better strategies for its prevention.

5 January 2022 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
MFMarcelo U. Ferreira
Marcelo U. Ferreira
RCRodrigo M. Corder
Rodrigo M. Corder
IJIgor C. Johansen
Igor C. Johansen
JKJohanna H. Kattenberg
Johanna H. Kattenberg
MMMarta Moreno
Marta Moreno
JVJoseph Vinetz
Joseph Vinetz
Background Low-density and asymptomatic Plasmodium vivax infections remain largely undetected and untreated and may contribute significantly to malaria transmission in the Amazon. Methods We analysed individual participant data from population-based surveys that measured P vivax prevalence by microscopy and polymerase chain reaction (PCR) between 2002 and 2015 and modelled the relationship between parasite density and infectiousness to vectors using membrane feeding assay data. We estimated the proportion of sub-patent (i.e., missed by microscopy) and asymptomatic P vivax infections and examined how parasite density relates to clinical manifestations and mosquito infection in Amazonian settings. Findings We pooled 24,986 observations from six sites in Brazil and Peru. P vivax was detected in 6 center dot 8% and 2 center dot 1% of them by PCR and microscopy, respectively. 58 center dot 5% to 92.6% of P vivax infections were asymptomatic and 61 center dot 2% to 96 center dot 3% were sub-patent across study sites. P vivax density thresholds associated with clinical symptoms were one order of magnitude higher in children than in adults. We estimate that sub-patent parasite carriers are minimally infectious and contribute 12 center dot 7% to 24 center dot 9% of the community-wide P vivax transmission, while asymptomatic carriers are the source of 28 center dot 2% to 79 center dot 2% of mosquito infections. Interpretation Asymptomatic P vivax carriers constitute a vast infectious reservoir that, if targeted by malaria elimination strategies, could substantially reduce malaria transmission in the Amazon. Infected children may remain asymptomatic despite high parasite densities that elicit clinical manifestations in adults. Copyright (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)